Open Access
*Corresponding author
Sahar S Atrees, biochemistry lecturer- Department of Chemistry, Faculty of Science, Fayoum University, 63514, Fayoum, Egypt
Tel: +2; tel. +201127768754 E-mail: ssa07@fayoum.edu.eg
Received: 10 September 2024
Accepted: 13 October 2024 Published online: 20 October 2024
Citation
Atrees SS (2024): Monosaccharide Management in Diabetes: A Pathway to Better Health Outcomes: An Article Review. BNNI (64) 53-67. doi: 10.21608/bnni.2024.387099
Diabetes is a common disorder that can afflict individuals of any age; about 537 million have diabetes across the world. This figure will increase to 634 million by 2035 and 783 million by 2045. Diabetes type 2 is the most common; it has also been proposed that a variety of pharmacologic approaches and non-pharmacological agents can enhance glycemic control in diabetic patients. Monosaccharides affect glycemic especially glucose causing diabetic mellitus due to raised glucose levels. Not only does glucose affect high glucose levels of sugar but other monosaccharides can contribute positively or negatively such as fructose, and trehalose. Moreover, many other monosaccharides contribute to type 2 diabetes, all have great interest and are discussed in this article, with the management of diabetic type 2 through monosaccharides. The conclusion states free sugars should be cut down on to regulate sugar levels, resistance starch doesn't affect glycemia, and nutritive sweetener management affects health. It doesn't relate to T2D, and trehalose affects glucose homeostasis by many pathways. The effects of each of these monosaccharides suggest the potential of non-pharmacological agents for the management of diabetes.